Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306989 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6342540 | 0.84 | PTGS2 (0.82) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6350704 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL6339181 | 0.82 | PTGS2 (0.84) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL5229590 | 0.82 | CYP2C9 (0.73) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL6341762 | 0.81 | PTGS2 (0.82) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6341438 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL6349534 | 0.81 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL8317359 | 0.81 | PTGS2 (0.83) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL6344510 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. | 2019-02-07 | — | — | US | disclosed |
| EP-3413889-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | Cocoon Biotech Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139684-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-101242875-A | Ophthalmic composition containing mucoadhesive polysaccharides capable of promoting corneal re-epithelialization | OPOCRIN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996033717-A1 | THERAPEUTIC COMPOSITION FOR ARTHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-31 | — | — | WO | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885PTGS1 539/4885CA12 4454/4885 |
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | MB, PTGES, PTGS1 | PTGS2 12/4885PTGS1 3/4885CA12 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.